Fujifilm to Expand its Viral Vector CDMO Services to Europe
TOKYO, October 7, 2020 - FUJIFILM Corporation (President: Kenji Sukeno) is expanding its gene therapy offering, with the addition of viral vector process development and GMP1 manufacturing services at FUJIFILM Diosynth Biotechnologies’ in the North East of the United Kingdom (UK).
FUJIFILM Diosynth Biotechnologies’ viral vector process development laboratories in the UK will be online from spring 2021. The laboratories will be outfitted with state-of-the-art equipment to support upstream (suspension and adherent) processes, downstream processing and analytical development. The GMP manufacturing capabilities are expected to be available from autumn 2021 and will support bulk drug substance production of investigational drugs used in early-stage clinical trials.
“FUJIFILM Corporation is committed to supporting the creation of new therapies for our customers through the stable supply of high-quality viral vectors that have the potential to have a profound impact for patients around the world,” said Takatoshi Ishikawa, senior executive vice president, general manager of Bio CDMO Division, FUJIFILM Corporation. “This initial investment will lay the groundwork to further grow our manufacturing services for gene therapies in Europe.”
Fujifilm first established a viral vector and vaccine development and manufacturing offering in 2014 at its College Station, Texas site, and has continued to invest and expand its services to position FUJIFILM Diosynth Biotechnologies as the leading contract development and manufacturing organization (CDMO).
“As a treatment modality, gene therapy holds tremendous promise to revolutionize the way patients are treated. We are committed to supporting our partners in their efforts to bring new therapies to market,” said Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. “This investment for production of early-stage investigational viral vector products is aligned with Fujifilm’s long-term strategy to provide process development and manufacturing solutions for its gene therapy partners. We will continue to invest in process development and manufacturing for gene therapies to meet the needs of our clients and drive forward progress in new drug development, to offer new treatment options to patients.”
1Good Manufacturing Practice
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com
All product and company names herein may be trademarks of their registered owners.
FUJIFILM Corporation Corporate Communications Division
TEL : +81 3-6271-2000
FUJIFILM Holdings America Corporation
TEL : +1 914-789-8523
FUJIFILM Corporation Bio CDMO Division
TEL : +81 3-6271-3025